Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000245 | 1.00 | NPSR1 (0.48) | NPSR1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL12786339 | 0.92 | NPC1 (0.44) | NPSR1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17051537 | 0.91 | NPC1 (0.48) | NPSR1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17051544 | 0.88 | NPC1 (0.50) | NPSR1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17051535 | 0.84 | KDM1A (0.49) | NPSR1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17051520 | 0.84 | CCR1 (0.48) | NPSR1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL10021910 | 0.83 | NPC1 (0.35) | NPSR1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17051517 | 0.83 | CCR1 (0.58) | NPSR1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17055533 | 0.82 | RAB9A (0.58) | NPSR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2608309 | 0.82 | NPC1 (0.60) | NPSR1NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227734-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2023-11-30 | — | — | WO | disclosed |
| US-10038143-B2 | Polymer compound, material for electronic elements, material for organic electroluminescent elements, and organic electroluminescent element | IDEMITSU KOSAN CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| US-20180019068-A9 | MODULATING ELECTRON TRANSFER DYNAMICS AT HYBRID INTERFACES VIA SELF-ASSEMBLED MULTILAYERS | The Florida State University Research Foundation, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-9761804-B2 | Oligomeric organic light emitting diode (OLED) materials containing multiple crosslinking functions | LOMOX LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170213978-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | NICHEM FINE TECHNOLOGY CO., LTD. (TW) | 2017-07-27 | — | — | US | disclosed |
| US-20170200563-A1 | MODULATING ELECTRON TRANSFER DYNAMICS AT HYBRID INTERFACES VIA SELF-ASSEMBLED MULTILAYERS | UNIV FLORIDA STATE RES FOUND (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2017076187-A1 | 1,4(1,4)-DIPHENYLHEXACYCLOPHANE-12,43-DIYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2017-05-11 | — | — | WO | disclosed |
| US-20150249215-A1 | POLYMER COMPOUND, MATERIAL FOR ELECTRONIC ELEMENTS, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, AND ORGANIC ELECTROLUMINESCENT ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-8779156-B2 | Analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-7425281-B2 | Liquid crystal compositions comprising an organogermanium compound and methods for using the same | DISPLAYTECH, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080204608-A1 | Liquid Crystal Element, Optical Path Deflecting Element, and Image Displaying Apparatus | RICOH COMPANY, LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080204608-A1 | Liquid Crystal Element, Optical Path Deflecting Element, and Image Displaying Apparatus | RICOH COMPANY, LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1237155-B1 | Optical recording film, method for manufacturing the same, optical recording medium, method for manufacturing the same, optical recording method, information recording/reproducing apparatus, information reproducing/recording method, computer system and video signal recording/reproducing system | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-7195719-B1 | High polarization ferroelectric liquid crystal compositions | DISPLAYTECH, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7195719-B1 | High polarization ferroelectric liquid crystal compositions | DISPLAYTECH, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170213978-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | OR51E2, OR10J3, ESR1 | NPSR1 3715/4885NPC1 2043/4885RAB9A 1508/4885 |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | NPSR1 200/4885NPC1 485/4885RAB9A 1943/4885 |
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | NPSR1 2347/4885NPC1 1372/4885RAB9A 1290/4885 |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | CYP17A1, HSD17B3, HSD17B1 | NPSR1 2524/4885NPC1 2862/4885RAB9A 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.